Country of origin: UK, AstraZeneca UK Ltd UK, Zeneca Indonesia, Zeneca UK
Pharm-Group: Inhibitors of luteinizing hormone secretion
Manufacturers: ICI Pharmaceuticals (UK), AstraZeneca UK Ltd (UK), Zeneca (Indonesia), Zeneca (UK)
International name: Goserelin
Dosage forms: depot capsules 10.8 mg, depot capsules 3.6 mg
Ingredients: Active ingredient - goserelin.
Indications for use: Hormone-dependent prostate cancer, hormone-dependent breast cancer in women during the reproductive period, endometriosis, uterine fibroids, dysfunctional uterine bleeding, in vitro fertilization methods (preparation for superovulation).
Contraindications: Hypersensitivity, pregnancy, lactation, childhood and adolescence (up to 14 years).
Side effects: In men - ureteral obstruction, spinal cord compression syndrome; in women - dryness of the vaginal mucosa, hot flashes, changes in mood and sexual desire, menopause, amenorrhea (after withdrawal), spotting (at first); instability of blood pressure, allergic reactions (skin rash, anaphylaxis).
Interaction: No information.
Overdose: No information.
Special instructions: Prescribe with caution if there is a risk of developing urinary tract obstruction and spinal cord compression syndrome. Repeated courses for benign gynecological diseases are not recommended due to the high likelihood of osteoporosis.
Literature: Encyclopedia of Medicines 2005.